Pancreatic Cancer - Pipeline Review, H2 2016

Date: December 28, 2016
Pages: 2006
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PE633B95348EN
Leaflet:

Download PDF Leaflet

Pancreatic Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Pipeline Review, H2 2016, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 15, 106, 112, 1, 3, 249, 38 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 7, 50 and 7 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Pancreatic Cancer Overview
Therapeutics Development
Pancreatic Cancer - Therapeutics under Development by Companies
Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
Pancreatic Cancer - Pipeline Products Glance
Pancreatic Cancer - Products under Development by Companies
Pancreatic Cancer - Products under Investigation by Universities/Institutes
Pancreatic Cancer - Companies Involved in Therapeutics Development
Pancreatic Cancer - Therapeutics Assessment
Drug Profiles
Pancreatic Cancer - Dormant Projects 1889
Pancreatic Cancer - Discontinued Products 1922
Pancreatic Cancer - Product Development Milestones 1929
Appendix 1942

LIST OF TABLES

Number of Products under Development for Pancreatic Cancer, H2 2016
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Development by Companies, H2 2016 (Contd..15)
Number of Products under Development by Companies, H2 2016 (Contd..16)
Number of Products under Development by Companies, H2 2016 (Contd..17)
Number of Products under Development by Companies, H2 2016 (Contd..18)
Number of Products under Development by Companies, H2 2016 (Contd..19)
Number of Products under Development by Companies, H2 2016 (Contd..20)
Number of Products under Development by Companies, H2 2016 (Contd..21)
Number of Products under Development by Companies, H2 2016 (Contd..22)
Number of Products under Development by Companies, H2 2016 (Contd..23)
Number of Products under Development by Companies, H2 2016 (Contd..24)
Number of Products under Development by Companies, H2 2016 (Contd..25)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Development by Companies, H2 2016 (Contd..22)
Products under Development by Companies, H2 2016 (Contd..23)
Products under Development by Companies, H2 2016 (Contd..24)
Products under Development by Companies, H2 2016 (Contd..25)
Products under Development by Companies, H2 2016 (Contd..26)
Products under Development by Companies, H2 2016 (Contd..27)
Products under Development by Companies, H2 2016 (Contd..28)
Products under Development by Companies, H2 2016 (Contd..29)
Products under Development by Companies, H2 2016 (Contd..30)
Products under Development by Companies, H2 2016 (Contd..31)
Products under Development by Companies, H2 2016 (Contd..32)
Products under Development by Companies, H2 2016 (Contd..33)
Products under Development by Companies, H2 2016 (Contd..34)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Pancreatic Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016
Pancreatic Cancer - Pipeline by 4SC AG, H2 2016
Pancreatic Cancer - Pipeline by AB Science SA, H2 2016
Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016
Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2016
Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016
Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2016
Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016
Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2016
Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2016
Pancreatic Cancer - Pipeline by Advaxis Inc, H2 2016
Pancreatic Cancer - Pipeline by Agenus Inc, H2 2016
Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2016
Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2016
Pancreatic Cancer - Pipeline by Alchemia Ltd, H2 2016
Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2016
Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2016
Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2016
Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2016
Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2016
Pancreatic Cancer - Pipeline by amcure GmbH, H2 2016
Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H2 2016
Pancreatic Cancer - Pipeline by Amgen Inc, H2 2016
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016
Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016
Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2016
Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2016
Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2016
Pancreatic Cancer - Pipeline by Aphios Corp, H2 2016
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2016
Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2016
Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2016
Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
Pancreatic Cancer - Pipeline by ArQule Inc, H2 2016
Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2016
Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H2 2016
Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016
Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
Pancreatic Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
Pancreatic Cancer - Pipeline by Bayer AG, H2 2016
Pancreatic Cancer - Pipeline by BeiGene Ltd, H2 2016
Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
Pancreatic Cancer - Pipeline by Berg LLC, H2 2016
Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2016
Pancreatic Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016
Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016
Pancreatic Cancer - Pipeline by BioLineRx Ltd, H2 2016
Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2016
Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2016
Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016
Pancreatic Cancer - Pipeline by Bionomics Ltd, H2 2016
Pancreatic Cancer - Pipeline by BioNTech AG, H2 2016
Pancreatic Cancer - Pipeline by BiOrion Technologies BV, H2 2016
Pancreatic Cancer - Pipeline by Biotest AG, H2 2016
Pancreatic Cancer - Pipeline by Biouniversa srl, H2 2016
Pancreatic Cancer - Pipeline by BLR Bio LLC, H2 2016
Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H2 2016
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H2 2016
Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H2 2016
Pancreatic Cancer - Pipeline by Cantargia AB, H2 2016
Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016
Pancreatic Cancer - Pipeline by Cavion LLC, H2 2016
Pancreatic Cancer - Pipeline by Celgene Corp, H2 2016
Pancreatic Cancer - Pipeline by Cellceutix Corp, H2 2016
Pancreatic Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016
Pancreatic Cancer - Pipeline by Celprogen Inc, H2 2016
Pancreatic Cancer - Pipeline by Celyad SA, H2 2016
Pancreatic Cancer - Pipeline by Centrose LLC, H2 2016
Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2016
Pancreatic Cancer - Pipeline by ChemoCentryx Inc, H2 2016
Pancreatic Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
Pancreatic Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
Pancreatic Cancer - Pipeline by Clovis Oncology Inc, H2 2016
Pancreatic Cancer - Pipeline by COARE Biotechnology Inc, H2 2016
Pancreatic Cancer - Pipeline by Concordia International Corp, H2 2016
Pancreatic Cancer - Pipeline by Confluence Life Sciences Inc, H2 2016
Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016
Pancreatic Cancer - Pipeline by CrystalGenomics Inc, H2 2016
Pancreatic Cancer - Pipeline by CTI BioPharma Corp, H2 2016
Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
Pancreatic Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 247

LIST OF FIGURES

Number of Products under Development for Pancreatic Cancer, H2 2016
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Pancreatic Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: